A Phase IIb, Randomised, Parallel, Double-Blind Placebo-Controlled and Open-Label Active Comparator Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes Mellitus
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 26 Oct 2018
At a glance
- Drugs MEDI 0382 (Primary) ; Liraglutide; Metformin
- Indications Obesity; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 18 Oct 2018 Planned End Date changed from 6 Mar 2020 to 9 Mar 2020.
- 31 Aug 2018 Biomarkers information updated
- 17 Jul 2018 Planned End Date changed from 5 Mar 2020 to 6 Mar 2020.